Sunday, November 22, 2026

NVIDIA Locks Lilly and Thermo Fisher Into BioNeMo as Global Drug Discovery Platform Race Intensifies

NVIDIA's BioNeMo has secured partnerships with Eli Lilly and Thermo Fisher, making GPU-backed protein modeling the shared infrastructure layer for commercial drug discovery. Five global competitors: including France's Owkin and UK-rooted Basecamp Research: are targeting the same stack. Platform decisions made in 2026 will determine which pipelines reach clinical trials by 2028.

This article was written by AI. Built from the source documents listed below. How we work

Source Trace Score2 source documents2 with a live linkVerifiability: Strong
NVIDIA Locks Lilly and Thermo Fisher Into BioNeMo as Global Drug Discovery Platform Race Intensifies
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

NVIDIA's BioNeMo platform has signed Eli Lilly and Thermo Fisher as anchor partners, turning GPU-backed protein modeling into the operating backbone of commercial drug discovery. The infrastructure race is now a commercial reality, not a research exercise.

Five platforms are competing for the same layer: Boltz Lab, Edison Kosmos, France's Owkin with OwkinZero, UK-rooted Basecamp Research's EDEN, and Natera. Each targets a different bottleneck in the global R&D pipeline. No single system controls the full stack.

Copenhagen signals the direction

Denmark's Novo Nordisk: one of Europe's most valuable companies: rose 24.9% over 30 days, driven by strong Q1 2026 earnings.1 Markets are pricing AI-augmented pipelines, not just near-term GLP-1 revenues. The company is exiting its internal cell therapy unit and licensing its Parkinson's program to Cellular Intelligence, an AI-native developer.1 Large pharma on three continents is watching.

Data infrastructure as the prerequisite

Tetrascience and Thermo Fisher are converting physical lab data into machine-readable formats. AI models cannot function without structured inputs. This partnership removes a foundational bottleneck common to every research institution globally.

FDA Fast Track designation adds further momentum. Compressed regulatory timelines improve economics for AI-assisted programs worldwide: including teams seeking eventual approvals in Europe, Japan, and emerging markets.

How the platforms differ across borders

Owkin's OwkinZero uses federated learning across clinical datasets, a model well-suited to Europe's strict patient-data regulations. Boltz Lab targets protein structure prediction. Edison Kosmos integrates genomics, imaging, and chemistry into a single multimodal model. Each system reflects a different regulatory and scientific tradition.

Commoditization is the likely endpoint. As molecular modeling converges, differentiation will shift to data access, regulatory track records, and integration depth with existing lab infrastructure: advantages that established global players hold.

The infrastructure bet

Pharma is buying AI infrastructure now, not running pilots. The BioNeMo-Lilly-Thermo Fisher axis leads today. But with five credible challengers spanning the US, Europe, and beyond, the race is far from settled.

Source documents

Via News is a conduit. We point to the source documents behind this report: we don't replace them. Trace any claim to its source and decide what to trust. How we source

Source Trace Score2 source documents2 with a live linkVerifiability: Strong
  1. [1]News articleYahoo Finance· May 11, 2026
    Novo Nordisk Refocuses On GLP‑1 As AI Partner Advances Parkinson’s Bet
  2. [2]News articleYahoo Finance· January 12, 2026
    NVIDIA BioNeMo Platform Adopted by Life Sciences Leaders to Accelerate AI-Driven Drug Discovery

Are you or your business in this article?

If something is wrong, out of context or missing, tell us. We correct errors with a dated note, and people named in an article can publish their response under it.

Correct, add context or respond →

Not a source? Spotted an error? Report an error

How this story was made

Spotted an error? Use “Correct this article” (bottom right), or select any sentence, to report it or respond to that point.

  1. Built from 2 source documents, dated 12 Jan 2026 to 11 May 2026
  2. Published 27 May 2026
  3. No responses yet from the people or organisations in this story. Are you in this story? Respond on the record ›
  4. Part of the Via News record, fingerprinted daily so it cannot be quietly rewritten. What that means › · Report an error ›

In this story · Knowledge Files

Via News Editorial Team

The Via News Editorial Team writes analysis and news from the Via News source-traceability system, under the editorial responsibility of L. Miguel Salvado, Editor. Each article is built only from source documents we hold and lists them at the end, so every claim can be checked. Articles generated with AI say so under the byline, as the EU AI Act requires.